AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BELLUSCURA PLC

Transaction in Own Shares May 13, 2025

7514_rns_2025-05-13_ba43fcd4-7b03-4ca2-876b-4eef58f01977.html

Transaction in Own Shares

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 4899I

Belluscura PLC

13 May 2025

13 May 2025

Belluscura plc

("Belluscura" or the "Company")

Response to Share Price Movement

Belluscura plc (AIM: BELL), a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies, notes the recent movements in its share price.

On Friday 9 May 2025 the Company issued a notification which included, inter alia, a comprehensive trading update and commencement of strategic review. There have been no notifiable developments since the publication of that announcement. As stated in that notification, the Company will provide further updates as and when appropriate.

Enquiries:

For further information please contact:

Belluscura plc Tel: +44 (0)20 3128 8100
Paul Tuson, Chairman

Robert Rauker, Chief Executive Officer
SPARK Advisory Partners Limited

Nominated Adviser
Tel: +44 (0)20 3368 3550
Neil Baldwin / Jade Bayat
Dowgate Capital Limited

Joint Broker
Tel: +44 (0)20 3903 7715
James Serjeant / Colin Climie (Sales and Corporate Broking)

Russell Cook / Daniel Ingram (Corporate Finance)
Allenby Capital Ltd

Joint Broker
Tel: +44 (0)20 3328 5656
Guy McDougall / Amrit Nahal (Sales and Corporate Broking)

Jeremy Porter / Lauren Wright (Corporate Finance)
MHP

Financial PR & Investor Relations
Tel: +44 (0)20 3128 8100

email: [email protected]
Katie Hunt/Matthew Taylor

For further information, please visit https://ir.belluscura.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

SPCBBGDUDUBDGUX

Talk to a Data Expert

Have a question? We'll get back to you promptly.